Abbott MediaRoom https://abbott.mediaroom.com/ Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes Wed, 27 May 2026 09:00:00 -0400 https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening https://abbott.mediaroom.com/2026-05-27-ACS-guideline-reaffirms-Abbott-leadership-in-noninvasive-colorectal-cancer-screening Wed, 27 May 2026 07:01:00 -0400 https://abbott.mediaroom.com/2026-05-27-ACS-guideline-reaffirms-Abbott-leadership-in-noninvasive-colorectal-cancer-screening Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 https://abbott.mediaroom.com/2026-05-26-Abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-ASCO-2026 Tue, 26 May 2026 09:00:00 -0400 https://abbott.mediaroom.com/2026-05-26-Abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-ASCO-2026 Abbott to highlight expanding cancer diagnostic portfolio and clinical evidence at Digestive Disease Week (DDW) 2026 https://abbott.mediaroom.com/press-releases?item=124750 Thu, 30 Apr 2026 09:00:00 -0400 https://abbott.mediaroom.com/press-releases?item=124750 Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform https://abbott.mediaroom.com/2026-04-28-Abbott-receives-FDA-clearance-and-CE-Mark-for-next-generation-Ultreon-TM-3-0-AI-powered-coronary-imaging-platform Tue, 28 Apr 2026 09:00:00 -0400 https://abbott.mediaroom.com/2026-04-28-Abbott-receives-FDA-clearance-and-CE-Mark-for-next-generation-Ultreon-TM-3-0-AI-powered-coronary-imaging-platform